LSO-087 Sub-optimal use of anti-malarial therapy for SLE in the Asia Pacific region; observations from the Asia Pacific lupus cohort

• DOI: 10.1136/lupus-2023-kcr.128
• Publication Date: 2023-08-07T07:50:28Z
• Authors: Rangi Kandane-Rat...; Alberta Hoi; Louthrenoo Worawit; Yi-Hsing Chen; Jiacai Cho; Aisha Lateef; Laniyati Hamijoyo; Shue Fen Luo; Yeong-Jian Jan Wu; Sandra Navarra; Leonid Zamora; Zhanguo Li; Sargunan Sockalingam; Yasuhiro Katsumata; Masayoshi Harigai; Yanjie Hao; Zhuoli Zhang; BMDB Basnayake; Madelynn Chan; Jun Kikuchi; Tsutomu Takeuchi; Shereen Oon; Sang-Cheol Bae; Sean O’Neill; Fiona Goldblatt; Kristine (Pek Lin...; Annie Hui Nee Law; Nicola Tugnet; Sunil Kumar; Naoaki Ohkubo; Michael Tee; Cherica Tee; Yoshiya Tanaka; Chak Sing Lau; Vera Golder; Mandana Nikpour; Eric Morand
• Keywords: Hydroxychloroquine; Asia-Pacific

<h3>Background</h3> The Asia-Pacific League of Associations for Rheumatology (APLAR) recently published consensus recommendations, including overarching principles, general management, and specific treatment strategies SLE in Asia. use hydroxychloroquine (HCQ) all patients was recommended unless contraindicated (statement 7).¹ We evaluated the current therapeutic practice with respect to anti-malarial Asia Pacific region against this recommendation. <h3>Methods</h3> used data from Lupus Collaboration (APLC) cohort, collected (meeting either ACR or SLICC criteria) between 2013 2020. Disease activity (SLEDAI-2K) medication details were captured at enrolment routine visits. defined categories based on glucocorticoid (GC), (AM) immunosuppressant (IS) each visit examined them relation clinical serological disease activity. <h3>Results</h3> analysed 4,086 41,653 visits data. Patients had no (i.e. SLEDAI-2K=0) 25.5% visits; alone 12.7% 34.8% visits, both 27% Regardless activity, 78% patient GC, 67% AM 61% IS. These proportions varied significantly among countries (figure 1). With regard use, majority HCQ (62% visits) a minority chloroquine (4%). <h3>Conclusions</h3> suboptimal across There are disparities management guidelines, highlighting need knowledge dissemination. <h3>References</h3> Mok CC, Hamijoyo L, Kasitanon N, Chen DY, S, Yamaoka K, <i>et al.</i> statements systemic lupus erythematosus. <i>The Lancet Rheumatology</i>. 2021;<b>3</b>(7):E517-E531.